64 related articles for article (PubMed ID: 15711827)
21. Active efflux kinetics of etoposide from rabbit small intestine and colon.
Kunta J; Yan J; Makhey VD; Sinko PJ
Biopharm Drug Dispos; 2000 Apr; 21(3):83-93. PubMed ID: 11113881
[TBL] [Abstract][Full Text] [Related]
22. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
23. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
24. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
[TBL] [Abstract][Full Text] [Related]
25. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
26. Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.
Ueno Y; Matsuda H; Mizutani H; Iwamoto T; Okuda M
Biol Pharm Bull; 2012; 35(1):54-8. PubMed ID: 22223337
[TBL] [Abstract][Full Text] [Related]
27. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
29. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
[TBL] [Abstract][Full Text] [Related]
30. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine.
Emi Y; Tsunashima D; Ogawara K; Higaki K; Kimura T
J Pharm Sci; 1998 Mar; 87(3):295-9. PubMed ID: 9523981
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
32. Intestinal iodide secretion and its dependence upon mucosal I- permeability.
Ondarra A; Ilundain A; Larralde J
Rev Esp Fisiol; 1985 Mar; 41(1):117-23. PubMed ID: 4001538
[TBL] [Abstract][Full Text] [Related]
33. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
[TBL] [Abstract][Full Text] [Related]
34. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
[TBL] [Abstract][Full Text] [Related]
35. Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.
Blandizzi C; De Paolis B; Colucci R; Di Paolo A; Danesi R; Del Tacca M
Toxicol Appl Pharmacol; 2001 Dec; 177(2):149-56. PubMed ID: 11740913
[TBL] [Abstract][Full Text] [Related]
36. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
Arakawa H; Shirasaka Y; Haga M; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2012 Sep; 33(6):332-41. PubMed ID: 22899169
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
Blandizzi C; De Paolis B; Colucci R; Lazzeri G; Baschiera F; Del Tacca M
Br J Pharmacol; 2001 Jan; 132(1):73-84. PubMed ID: 11156563
[TBL] [Abstract][Full Text] [Related]
38. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
[TBL] [Abstract][Full Text] [Related]
39. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies.
Hu ZP; Yang XX; Chen X; Chan E; Duan W; Zhou SF
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):575-80. PubMed ID: 17270505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]